SOX11 was previously reported in a varying number of glial neoplasms, ranging from 93–100% of astrocytomas, using polyclonal antibody [18], to a more limited 50% of gliomas when monoclonal antibody MRQ-58 was used. This evidence concerns the gene SOX11 and central nervous system cancer.